Discussion 1) At the end of the trial it was recorded that 100-102 participants received an active dose of cagrilintide, 99 participants were administered a 3.0 mg dose of liraglutide and 101 participants were given volume-matched placebo
This revolutionary medication for weight loss and diabetes mimics the effects of the hormones GLP-1 and GIP, which are crucial for regulating appetite and managing blood sugar levels
Assessed were the inferior caval vein (which was occluded), right ovarian vein (which appears as blind vessel due to the infrarenal occlusion), and left ovarian vein (which serves as a bypassing pathway) (Vukojevic et al., 2018)
After the initial diet-induced weight loss, participants were randomized (1:1:1:1) to one of four treatment arms: placebo + usual physical activity (placebo), placebo + exercise (exercise alone), liraglutide + usual physical activity (liraglutide alone), or liraglutide + exercise (combined treatment)